MONMOUTH JUNCTION, N.J., Oct. 20, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) has accepted an invitation to speak at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference at 4:40 p.m. EDT Tuesday, October 25th at the Palace Hotel in New York.
Daniel Greenleaf, President and CEO of VioQuest, will provide a company overview and an update on the development of the company's in-licensed targeted oncology therapeutics, including VQD-001 Sodium Stibogluconate (SSG), which recently began a Phase I clinical trial at the Cleveland Clinic Cancer Center.
VioQuest Pharmaceuticals is one of over 90 public and private emerging growth biotechnology companies schedule to present at the conference.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc.'s strategy is to acquire, develop, and commercialize targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. The Company is developing two novel anti-cancer agents VQD-001 and VQD-002 for the treatment of melanoma, myeloma, lymphoma; and breast, ovarian, pancreatic, colorectal cancers, respectively. VioQuest's life science subsidiary, Chiral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improves the safety, efficacy and manufacturing efficiency of pharmaceutical products. Through Chiral Quest, VioQuest provides products and services to fine chemical manufacturers and twelve of the top eighteen pharmaceutical companies worldwide. For more information please visit www.vioquestpharm.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.